Rendering of 3675 Market Street, Philadelphia, PA
PHILADELPHIA, PA—Global biotechnology company Amicus Therapeutics will occupy space in uCity Square's newest building, 3675 Market Street, for its newly-announced Global Research and Gene Therapy Center of Excellence.
With the Amicus announcement, 3675 Market is now 90% leased just 90 days after opening in November. Amicus's commitment in the building totals 75,000 square feet of office and lab space over three floors and is expected to be open in the second half of 2019.
The space will eventually hold up to 200 employees. A group of Amicus researchers is already occupying space in the building as a client of BioLabs@CIC Philadelphia, a state-of-the art co-working wet lab and office facility.
“Like all of our facilities, the BioLabs@CIC Philadelphia site is designed to stimulate exciting science and creative collaboration,” says Dr. Laura Holberger, vice president of strategic partnerships, BioLabs. “Amicus brings valuable real-life experience and world-class science to our Philadelphia community and our national network.”
Developed by Wexford Science & Technology in partnership with the University City Science Center and real estate investment trust Ventas, 3675 Market Street is a 14-story, 345,000-square-foot building that combines several unique but complementary innovation assets including CIC Philadelphia, BioLabs@CIC Philadelphia, Science Center commercialization programs, Quorum, Venture Café Philadelphia, and FirstHand.
“We're thrilled to welcome Amicus Therapeutics to 3675 Market,” says Science Center president and CEO Steve Zarrilli. “The establishment of the Global Research and Gene Therapy Center of Excellence is a testament to the vitality of the vibrant community here at uCity Square and Philadelphia as a leader in biotechnology and gene therapy research.”
3675 Market is the latest addition to uCity Square, a 6.5 million square-foot mixed-use knowledge community consisting of office, laboratory, clinical, residential, and retail space to enable university and corporate research, entrepreneurial activity, and community engagement.
“Attracting biotechnology industry leaders like Amicus to uCity Square validates the power of the knowledge community business model in developing a platform that encourages innovation through collaboration with leading research universities,” says Joe Reagan, senior vice president at Wexford Science & Technology. “The decision to come to 3675 is a testament to the diverse combination of partners and offerings within our ecosystem that provide flexibility and scalability for organizations like Amicus.”
Amicus Therapeutics chairman and CEO John F. Crowley acknowledged the proximity to collaborators at the University of Pennsylvania and other major academic centers and hospitals in the area as a tremendous opportunity to advance their commitment to gene therapies and novel high-quality medicines for people living with rare metabolic diseases as part of their announcement.
Want to continue reading?
Become a Free ALM Digital Reader.
Once you are an ALM Digital Member, you’ll receive:
- Breaking commercial real estate news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical coverage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
*May exclude premium content© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Steve Lubetkin
Steve Lubetkin is the New Jersey and Philadelphia editor for GlobeSt.com. He is currently filling in covering Chicago and Midwest markets until a new permanent editor is named. He previously filled in covering Atlanta. Steve’s journalism background includes print and broadcast reporting for NJ news organizations. His audio and video work for GlobeSt.com has been honored by the Garden State Journalists Association, and he has also been recognized for video by the New Jersey Chapter of the Society of Professional Journalists. He has produced audio podcasts on CRE topics for the NAR Commercial Division and the CCIM Institute. Steve has also served (from August 2017 to March 2018) as national broadcast news correspondent for CEOReport.com, a news website focused on practical advice for senior executives in small- and medium-sized companies. Steve also reports on-camera and covers conferences for NJSpotlight.com, a public policy news coverage website focused on New Jersey government and industry; and for clients of StateBroadcastNews.com, a division of The Lubetkin Media Companies LLC. Steve has been the computer columnist for the Jewish Community Voice of Southern New Jersey, since 1996. Steve is co-author, with Toronto-based podcasting pioneer Donna Papacosta, of the book, The Business of Podcasting: How to Take Your Podcasting Passion from the Personal to the Professional. You can email Steve at [email protected].
